What is the difference between AOD-9604 and Mod GRF 1-29?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. Mod GRF 1-29: Modified GHRH analog; binds GHRH receptors with improved stability to produce physiological GH pulses when combined with a GHRP

Is Mod GRF 1-29 FDA approved?

Mod GRF 1-29 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Mod GRF 1-29 administered in research settings?

In research settings, Mod GRF 1-29 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs Mod GRF 1-29

Peptide Comparison

AOD-9604 vs Mod GRF 1-29

Name: AOD-9604 vs Mod GRF 1-29 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

195 providers listed

Full AOD-9604 profile →

Mod GRF 1-29

CJC-1295 no DAC

PerformanceNot EvaluatedResearch Only

Half-life: ~30 minutes

15 providers listed

Full Mod GRF 1-29 profile →

Bottom line

Mod GRF 1-29 carries stronger published evidence (RCT, 2 key studies) than AOD-9604 (Animal, 1); both are research compounds.

Quick Verdict

AOD-9604

Evidence

Preclinical

Half-life

30–60 minutes

Mod GRF 1-29

Evidence

Emerging Clinical

Half-life

~30 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Mod GRF 1-29
Oral administration option	AOD-9604
Lower typical price per mg	Mod GRF 1-29
More provider options (195 vs 15)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

Mod GRF 1-29

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

~30 minutes

FDA Status

nomination withdrawn

not evaluated

Admin Routes

subcutaneous, oral

subcutaneous

Availability

Research Only

Providers

195 listed

15 listed

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

GHRH analog (CJC-1295 without DAC). Related to sermorelin but structurally distinct (tetrasubstituted AAs). No FDA approval. Not on FDA 503A bulks list. WADA prohibited. Research chemical.

Research Evidence

AOD-9604

PreclinicalAnimal · 1 key study · dated evidence base — most recent 2001

Mod GRF 1-29

Emerging ClinicalRCT · 2 key studies · dated evidence base — most recent 1997

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

Mod GRF 1-29

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About Mod GRF 1-29

Modified GHRH analog; binds GHRH receptors with improved stability to produce physiological GH pulses when combined with a GHRP

Research Areas

pituitary GHRH receptor agonism — pulsatile GH stimulationimproved proteolytic stability vs native GHRH 1-29synergistic GH release when combined with GHRPs (ipamorelin, GHRP-6)~30 min half-life — requires dosing at each session vs CJC-1295 with DAC (weekly)

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Mod GRF 1-29

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Used Together?

Mod GRF 1-29

Ipamorelin
Research suggests Ipamorelin and Mod GRF 1-29 may produce enhanced growth hormone pulse effects when combined. Ipamorelin acts via ghrelin receptors (GHSR) while Mod GRF 1-29 acts via GHRH receptors — distinct pathways that research suggests may amplify GH secretion when activated together.

Price (per mg)

AOD-9604

$9.00/mg

$7.46 – $12.15 range

61 vendors

View price index →Find providers →

Mod GRF 1-29

$7.50/mg

$7.25 – $8.42 range

7 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

195 listed

Browse directory →

Providers offering

Mod GRF 1-29

15 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs Mod GRF 1-29 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/aod-9604/mod-grf-1-29

https://peptidebase.io/peptides/compare/aod-9604/mod-grf-1-29 Methodology License Download JSON Download CSV